Handelsbanken Fonder AB Sells 13,500 Shares of Aurinia Pharmaceuticals Inc $AUPH

Handelsbanken Fonder AB decreased its stake in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) by 22.2% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 47,200 shares of the biotechnology company’s stock after selling 13,500 shares during the period. Handelsbanken Fonder AB’s holdings in Aurinia Pharmaceuticals were worth $400,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Hussman Strategic Advisors Inc. increased its position in Aurinia Pharmaceuticals by 70.0% during the second quarter. Hussman Strategic Advisors Inc. now owns 357,000 shares of the biotechnology company’s stock worth $3,024,000 after acquiring an additional 147,000 shares during the period. Strs Ohio acquired a new position in shares of Aurinia Pharmaceuticals during the 1st quarter worth approximately $636,000. Public Employees Retirement System of Ohio bought a new position in shares of Aurinia Pharmaceuticals during the second quarter worth approximately $282,000. Acropolis Investment Management LLC acquired a new stake in shares of Aurinia Pharmaceuticals in the second quarter valued at approximately $242,000. Finally, Vident Advisory LLC acquired a new stake in shares of Aurinia Pharmaceuticals in the first quarter valued at approximately $232,000. Institutional investors and hedge funds own 36.83% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Jefferies Financial Group raised Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their price objective for the company from $10.00 to $21.00 in a report on Friday, November 7th. Bloom Burton cut shares of Aurinia Pharmaceuticals from a “moderate buy” rating to a “hold” rating in a research report on Wednesday, November 5th. Weiss Ratings reissued a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a report on Wednesday, October 8th. Finally, Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $15.00 price target (up previously from $9.00) on shares of Aurinia Pharmaceuticals in a report on Wednesday, November 5th. Two equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, Aurinia Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $17.67.

Aurinia Pharmaceuticals Stock Down 1.0%

Shares of NASDAQ AUPH opened at $16.20 on Monday. The company has a 50 day simple moving average of $13.25 and a 200 day simple moving average of $11.00. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.23 and a quick ratio of 4.63. Aurinia Pharmaceuticals Inc has a 1 year low of $6.55 and a 1 year high of $16.48. The firm has a market cap of $2.14 billion, a PE ratio of 37.68 and a beta of 1.30.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.16 by $0.07. The firm had revenue of $73.47 million during the quarter, compared to analysts’ expectations of $67.70 million. Aurinia Pharmaceuticals had a net margin of 23.31% and a return on equity of 20.06%. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. On average, research analysts forecast that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current year.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.